Vertex CF Drug Combo Significantly Improves Lung Function

Vertex Pharmaceuticals Inc says results from two Phase 3 studies of its lumacaftor-ivacaftor drug combination showed statistically significant improvements in lung function (ppFEV1) in cystic fibrosis patients (12+) who have two copies of the F508del mutation.


Market Analysis: Aerosol Therapy

As the number of chronic lung patients continues to grow, today’s aerosol therapy products are providing high-quality, cost-efficient medication delivery.


Electromed Partners On Launch Of New Children’s Book

Electromed Inc has joined in the launch of a new children’s book, Healthy Choices, Happy Kids: Making Good Choices with Everyday Care, and will include a free copy of the book with all SmartVest shipments for newly prescribed patients 10 years old and younger (while supplies last).